Myocardial Injury & Severe Pneumococcal Pneumonia

Status Terminated

Clinical Trial Summary

Hypothesis: The "novo" cardiovascular events (CVE)in patients with severe community-acquired pneumonia (CAP) are frequent (17%) and could be associated with both direct pneumococcal myocardial invasion, toxin delivery (pneumolysin) or different biomarkers (histones, NETs(neutrophil extracellular traps), IL (Interleukin)-1b,h-Fabp (heart-Fatty acid bindding protein) ).The CVE frequency and its impact on outcome in patients without prior heart disease (CP) has not been studied. Objectives:1) To determine the incidence of myocardian injury (MI) and CVE in patients with CAP without CP evaluated by non-invasive techniques (Echocardiograph and MRI) and biomarkers levels (Tn-I (Troponin I), h-Fabp, NT-proBNP (N-terminal pro-brain natriuretic peptide) histones, NETs, IL 1b); 2) To assess if DMA and CVE are related to the etiology and their impact on outcome , 3) To investigate the presence of myocardial scarring by MRI and its relationship with etiology and MI, and 4) To identify prognostic factors of DMA and CVE to determine level of risk.

Clinical Trial Description

Area: Intensive care unit (ICU) of the participating hospitals. Patients: Forty patients with CAP without heart disease history will be included consecutively (20 patients with pneumococcal CAP and 20 patients with non-pneumococcal CAP).Ten healthy volunteers (controls) are included. Variables: Epidemiological, clinical and hemodynamic variables are recorded. Presence of MI and CVE measured by echocardiography and by biomarkers will be evaluated during the ICU stay. Presence of scarring miocardic by MRI technique will be determined at month 6 since ICU admission. Statistical analysis: Categorical (Fisher's exact test) and continuous variables( Wilconxon and Anova) will be used to determine differences between them. The Pearson correlation, ROC (discriminatory power) and logistic regression analysis(independent association) will be used to determine the association between variables and outcome. A p-value of 0.05 will be considered significant. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03058211
Study type	Observational [Patient Registry]
Source	Hospital Universitari Joan XXIII de Tarragona.
Contact
Status	Terminated
Phase
Start date	March 1, 2018
Completion date	December 31, 2019

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06032572` - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)	N/A
Recruiting	`NCT05846893` - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease	N/A
Completed	`NCT04153006` - Comparison of Fingerstick Versus Venous Sample for Troponin I.
Completed	`NCT01205776` - EXCEL Clinical Trial	N/A
Active, not recruiting	`NCT04555174` - BIOFLOW-VIII All-comers Orsiro Mission Safety and Performance Registry
Recruiting	`NCT04582877` - Pressure Guidewire System Multi-center, Prospective, Self-Control, Clinical Trial	N/A
Recruiting	`NCT04390672` - Multivessel TALENT	N/A
Recruiting	`NCT03265535` - Validation of a Single Rest-Stress Imaging Protocol for Myocardial Perfusion Imaging
Not yet recruiting	`NCT04522583` - Increased CRP Concentrations in Patients Admitted to the Emergency Department With Troponin Elevation Aids to Rule Out Coronary Ischemia
Completed	`NCT02554006` - Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings	N/A
Completed	`NCT02510547` - Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial	Phase 4
Terminated	`NCT02407626` - Optimization of Cardioprotection in Diabetic Patients Undergoing Cardiac Surgery	N/A
Active, not recruiting	`NCT02189499` - Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent	Phase 2
Completed	`NCT02264717` - Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease	N/A
Completed	`NCT02197065` - Pilot Study of Atorvastatin for Orthopedic Surgery Patients	Phase 2
Recruiting	`NCT01681381` - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization	N/A
Terminated	`NCT01892917` - BIOFLOW-III Hungary Satellite Registry	N/A
Completed	`NCT01655043` - Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI	Phase 2
Completed	`NCT01679886` - Comparison of Rubidium PET and SPECT With CZT Crystals for Detection of Myocardial Ischemia in Overweighed Patients and Women	N/A
Completed	`NCT02707445` - Genotyping Influences Outcome of Coronary Artery Stenting	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Myocardial Injury and Severe Pneumococcal Pneumonia — NEUMOCAR

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms